Summary & Overview
HCPCS J9183: Gemcitabine Intravesical System, 225 mg
HCPCS Level II code J9183 identifies a 225 mg intravesical formulation of gemcitabine used for direct bladder instillation. Intravesical gemcitabine is an important option in the management of non-muscle invasive bladder cancer and other localized urothelial neoplasms; having a distinct HCPCS Level II code enables clearer billing, tracking of utilization, and payer policy development for this specific preparation. Nationally, precise coding supports reimbursement clarity and clinical inventory management for infusion centers and urology practices.
Key payers in the overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an explanation of what the code represents and the typical settings where the service is delivered. The publication provides benchmarks and payer coverage considerations, summarizes relevant billing context for outpatient infusion and urology clinic workflows, and outlines clinical context for intravesical gemcitabine preparations. Missing input fields are noted as unavailable.
This summary is designed for billing managers, revenue cycle leaders, clinical pharmacists, and policy analysts seeking a concise national-level reference on HCPCS Level II code J9183 and its role in intravesical chemotherapy billing and service delivery.
Billing Code Overview
HCPCS Level II code J9183 describes gemcitabine intravesical system, 225 mg. This code represents a localized intravesical chemotherapy formulation of gemcitabine intended for direct instillation into the urinary bladder.
-
Service type: Intravesical chemotherapy administration
-
Typical site of service: Ambulatory infusion centers, hospital outpatient departments, and urology clinics where intravesical therapies are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 68-year-old male with non–muscle-invasive bladder cancer (NMIBC) who has had a recent transurethral resection of bladder tumor (TURBT) and is scheduled to receive intravesical chemotherapy using the gemcitabine intravesical system, J9183 (225 mg). The clinical workflow begins in the urology clinic where the physician reviews the operative pathology confirming Ta or T1 disease or carcinoma in situ, counsels the patient on intravesical therapy options, and obtains informed consent. On the day of treatment, the patient presents to an outpatient urology procedure suite or ambulatory infusion center. A nurse reviews allergies and vital signs, places the patient in lithotomy position, performs sterile urethral catheterization, evacuates urine, and instills the J9183 gemcitabine intravesical system into the bladder according to manufacturer and institutional protocol. The patient retains the intravesical agent for the prescribed dwell time (often 1–2 hours) and then voids; postprocedure monitoring is brief and the patient is discharged home with follow-up instructions. Typical sites of service are outpatient urology clinics, ambulatory surgery centers, or hospital outpatient departments where intravesical chemotherapy is delivered and documented in the medical record for scheduling, billing, and subsequent surveillance cystoscopy visits.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
59 |